Summarizing the current knowledge on eotaxins in cancer, we might suggest that currently CCL11 is the best candidate for a biomarker which may be used in the future not only in the detection of cancerous diseases (as a marker of ongoing inflammation) but also as a marker of treatment efficacy (as a marker od decreasing inflammation). The gene discussed is CCL11; the disease is cancer.